Deutsche Bank AG Buys 37,907 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)

Deutsche Bank AG increased its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 15.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 277,853 shares of the company’s stock after buying an additional 37,907 shares during the period. Deutsche Bank AG owned 0.19% of Denali Therapeutics worth $5,663,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of DNLI. Barclays PLC increased its stake in shares of Denali Therapeutics by 101.4% during the third quarter. Barclays PLC now owns 255,883 shares of the company’s stock worth $7,454,000 after purchasing an additional 128,823 shares during the period. SG Americas Securities LLC lifted its holdings in shares of Denali Therapeutics by 128.8% during the fourth quarter. SG Americas Securities LLC now owns 11,003 shares of the company’s stock worth $224,000 after buying an additional 6,195 shares in the last quarter. KBC Group NV boosted its position in shares of Denali Therapeutics by 75.8% in the fourth quarter. KBC Group NV now owns 6,334 shares of the company’s stock valued at $129,000 after acquiring an additional 2,731 shares during the period. China Universal Asset Management Co. Ltd. grew its stake in shares of Denali Therapeutics by 10.8% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 30,517 shares of the company’s stock valued at $622,000 after acquiring an additional 2,982 shares in the last quarter. Finally, abrdn plc increased its position in Denali Therapeutics by 10.6% during the fourth quarter. abrdn plc now owns 402,282 shares of the company’s stock worth $8,199,000 after acquiring an additional 38,603 shares during the period. Institutional investors and hedge funds own 92.92% of the company’s stock.

Denali Therapeutics Stock Down 2.7%

Shares of Denali Therapeutics stock opened at $13.78 on Monday. The company has a market cap of $2.00 billion, a PE ratio of -4.99 and a beta of 1.49. Denali Therapeutics Inc. has a 52 week low of $10.57 and a 52 week high of $33.33. The business has a 50 day moving average price of $14.11 and a 200-day moving average price of $19.55.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.07). During the same period in the previous year, the firm earned ($0.68) EPS. As a group, research analysts anticipate that Denali Therapeutics Inc. will post -2.71 EPS for the current year.

Analyst Ratings Changes

Several research analysts have recently commented on the stock. HC Wainwright lowered their target price on shares of Denali Therapeutics from $80.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, May 7th. Oppenheimer dropped their target price on shares of Denali Therapeutics from $50.00 to $42.00 and set an “outperform” rating for the company in a research report on Monday, March 3rd. William Blair raised shares of Denali Therapeutics to a “strong-buy” rating in a report on Thursday, April 24th. Wedbush decreased their price objective on shares of Denali Therapeutics from $32.00 to $30.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 7th. Finally, Cantor Fitzgerald upgraded Denali Therapeutics from a “neutral” rating to an “overweight” rating in a research note on Thursday, April 10th. One analyst has rated the stock with a hold rating, fourteen have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $33.79.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.